Clinical trial
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced…
NCT00084617 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00084617 |
|---|---|
| Title | Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma |
| Official title | Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer |
| Intervention type | Drug |
| Interventions | oxaliplatin, irinotecan hydrochloride, capecitabine |
| Enrollment | 39 |
| Start date | Mar 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jun 11, 2004 |
| Last update posted | May 1, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: